Status: Recruiting
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CD70-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CD70-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Participants needed: 90
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Chongqing Precision Biotech Co., LtdUpdated: Oct 2, 2025Locations: 1
Eligibility criteria
Age ≥18 years, regardless of gender; [+16]
Prior treatment with anti-CD70 therapies; [+18]